Compared to patients with symptoms, those diagnosed by surveillance were more likely to be female (female 41.7% vs. 30.4%, p = 0.018), have better ECOG performance (ECOG 0 78.7% vs. 60.9%, p < 0.001), more viral etiology (HBV 32.8% vs. 15.2%; HCV 30.6% vs. 14.1%, p < 0.001), more likely to be diagnosed with mUICC stage 1 or 2 (72.3% vs. 39.1%, p < 0.001), and have lower serum tumor marker levels (median AFP 9.2 vs. 35.2 μg/mL, p < 0.001; median PIVKA II 33 vs.1725 mAU/mL, p < 0.001). The gene discussed is AFP; the disease is neoplasm.